Symptomatic Carotid Stenosis: TIA Timing and CEA Urgency

June 2, 2026

Definition: What Makes a Patient Symptomatic?

A patient is symptomatic for carotid stenosis if they have had a TIA or ipsilateral stroke within the preceding 6 months attributable to the stenotic artery. Specifically:

TIA: Transient focal neurological symptoms (limb weakness, speech difficulty, visual loss) resolving within 24 hours, caused by embolism from ipsilateral carotid plaque
Stroke: Completed ischemic stroke in the ipsilateral hemisphere or retina with residual deficit
Amaurosis fugax: Transient monocular visual loss (retinal TIA) from the ipsilateral ophthalmic artery

Symptoms must be ipsilateral to the stenotic artery. A left-sided stroke with right carotid stenosis does not make the right carotid symptomatic.

Use the NASCET Calculator to classify stenosis severity. This guide covers the clinical decision pathway after classification.

Why Timing Matters: Early Stroke Risk After TIA

The stroke risk following a TIA from carotid disease is front-loaded in the first days. This changes the clinical urgency:

Time after TIA/minor stroke	Cumulative ipsilateral stroke risk
48 hours	~3–5%
7 days	~7–10%
14 days	~11.5%
30 days	~15–18%

Key implication: Most of the benefit from early CEA comes from operating before the next stroke occurs. Waiting weeks after a TIA means a substantial fraction of the preventable strokes have already happened.

NASCET Trial: The Evidence Base

The 1991 NASCET trial (North American Symptomatic Carotid Endarterectomy Trial) is the foundation for all symptomatic carotid stenosis management. Key results for symptomatic patients:

NASCET %	2-year ipsilateral stroke risk (medical alone)	2-year risk (CEA)	Absolute risk reduction	NNT
≥ 70%	26%	9%	17%	~6
50–69%	22%	15.7%	6.5% (over 5 yrs)	~15
< 50%	—	CEA offers no benefit	—	—

For symptomatic patients with ≥70% NASCET stenosis: CEA is strongly indicated. The evidence is compelling and widely accepted.

For 50–69%: Benefit exists but is moderate. Patient selection matters — subgroups with hemispheric symptoms, male sex, and ≥50% stenosis on contralateral side had better outcomes with CEA in NASCET subgroup analysis.

Below 50%: No CEA benefit demonstrated. Medical management only.

Timing of CEA: The 2-Week Window

Guidelines uniformly recommend CEA within 2 weeks of the symptomatic event for eligible patients with ≥70% stenosis. The evidence:

NASCET and ECST pooled analysis: CEA benefit is maximal when performed within 2 weeks (NNT ~6); this falls to ~12 after 2 weeks and is negligible after 12 weeks
The benefit of early intervention outweighs the slightly increased perioperative risk of operating on recently symptomatic patients in most cases

Exception — minor stroke (not TIA): For patients with a completed stroke (not TIA) as the index event, the perioperative risk of urgent CEA (within 48 hours) is higher than for TIA. Most guidelines suggest waiting 3–14 days after minor stroke to allow the infarct to stabilize before operating — but still within the 2-week window where possible.

Contraindications to urgent CEA:

Large hemispheric infarct (surgically operating risks hemorrhagic transformation)
Significant neurological deficit that hasn’t stabilized
Surgical fitness concerns — active cardiac instability, anticoagulation requirements
Local surgical expertise unavailable within timeframe

Clinical Pathway for Symptomatic Patients

Step 1 — Confirm etiology: TIA or stroke must be attributable to ipsilateral carotid artery embolism. Exclude cardioembolic sources (AF, recent MI, valvular disease), lacunar infarcts, and contralateral carotid disease.

Step 2 — Image the carotid: Duplex ultrasound as initial screen; CTA or MRA for confirmation before surgical planning. See Carotid Duplex Ultrasound Velocity Criteria for velocity thresholds.

Step 3 — Calculate NASCET% using the NASCET Calculator:

≥70%: Refer for urgent CEA — target within 2 weeks
50–69%: Discuss with neurovascular surgery — moderate benefit, individual decision
Below 50%: Best medical therapy only (see below)

Step 4 — Start medical therapy immediately, regardless of whether surgery is planned:

Antiplatelet: aspirin 75–325 mg daily (or aspirin + clopidogrel for high-risk short-term; discussed further in Carotid Stenosis Medical Management)
High-intensity statin: atorvastatin 40–80 mg daily (even if LDL appears normal)
Blood pressure control: target < 140/90 mmHg, but avoid hypotension in severe bilateral stenosis
Glucose control, smoking cessation, lifestyle modification

Step 5 — CEA or CAS? For symptomatic patients, CEA is preferred in most guidelines (lower stroke risk than CAS in symptomatic patients, especially in older patients). See CEA vs Carotid Artery Stenting for the evidence comparison.

Perioperative Risk: When Surgery Risk Exceeds Benefit

CEA benefit is only realized when the perioperative stroke/death risk is low. NASCET trial CEA perioperative risk: ~5.8% combined stroke and death.

Guidelines state that CEA is indicated in symptomatic patients with ≥70% stenosis when perioperative stroke/death risk is < 6%. If institutional or surgeon-specific risk exceeds this threshold, the risk-benefit equation shifts.

Factors that increase perioperative risk:

Age > 80 (higher but still may benefit — individual assessment)
Significant cardiac disease (recent MI within 6 weeks, unstable angina)
Contralateral ICA occlusion
Prior ipsilateral CEA or neck radiation
High carotid bifurcation (anatomically challenging)

In high-risk surgical candidates with ≥70% symptomatic stenosis, CAS may be considered despite the modestly higher stroke risk — because leaving severe symptomatic stenosis untreated carries a higher risk than the procedure.

Clinical note: This guide is for trained clinicians. Management decisions require multidisciplinary assessment including neurology, vascular surgery, and interventional radiology input. Individual patient factors override general algorithms.